Trials / Completed
CompletedNCT02698410
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
Efficacy and Safety of Lanreotide ATG 120 mg in Combination With Temozolomide in Subjects With Progressive Well Differentiated Thoracic Neuroendocrine Tumors. A Phase II, Multicentre, Single Arm, Open-label Trial.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the protocol is to evaluate the efficacy and safety of Lanreotide ATG 120 mg in combination with Temozolomide in subjects with unresectable advanced neuroendocrine tumours of the lung or thymus as Disease Control Rate at 9 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanreotide (Autogel formulation) and Temozolomide |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2019-02-08
- Completion
- 2019-06-18
- First posted
- 2016-03-03
- Last updated
- 2020-10-01
- Results posted
- 2020-10-01
Locations
10 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02698410. Inclusion in this directory is not an endorsement.